435 Studies Now Enrolling
An International Phase 1/2 Study of GRT-C901/GRT-R902, a Neoantigen Cancer Vaccine, in Combination with Immune Checkpoint Blockade for Patients with Advanced Solid Tumors
Study of a Neoantigen Cancer Vaccine in Patients with Advanced Solid Tumors (Bladder, Colon, Stomach, Lung, Esophageal, or Rectal Cancer)
| Sponsor: | Gritstone Oncology |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAS0000 |
| U.S. Govt. ID: | NCT03639714 |
| Contact: | Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
Additional Study Information:
The purpose of this research study is to learn more about an experimental personalized vaccine that has two components called GRT-C901 and GRT-R902. We will learn more about the effects of this vaccine on your cancer when used together with approved medications that activate the immune system, nivolumab (Opdivo) as well as ipilimumab (Yervoy), which are approved by the United States Food and Drug Administration (FDA) for some of the types of cancer that will be treated on this study. The vaccine is specific to you and your tumor, and cannot be used to treat any other patients.
This study is closed
Do You Qualify?
| Are you 18 years of age or older? | Yes | No |
| Do you have bladder, colon, stomach, lung, esophageal, or rectal cancer? | Yes | No |
| Do you have tumor tissue already available for testing? | Yes | No |
| Are you willing to undergo biopsies prior to receiving study treatment and also while receiving study treatment? | Yes | No |